A Study of RD14-01 in Patients With Advanced Solid Tumors

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

This study will evaluate the safety and tolerability of RD14-01, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ advanced solid tumors.

Early Phase 1

Shen Lin